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ABSTRACT
Twenty-five isolates of Pseudomonas aeruginosa with different meropenem susceptibilities were subjected
to quantitative RT-PCR for analysis of transcription levels of oprD, mexB and mexD, and, in selected
isolates, PA3720, which is hyper-expressed in nalC efflux mutants. Regulator genes of efflux pump
MexAB–OprM, mexR and PA3721 (putative) were sequenced in selected isolates. The potential for
mathematical reconstruction of the ideal susceptible population using normalised resistance interpret-
ation (NRI) was also studied. In three isolates with intermediate susceptibility to meropenem (according
to Swedish breakpoints), a reduction in MIC from 4 to 2 mg ⁄L was observed with efflux inhibitor MC-
207,110. These isolates would be considered susceptible according to British Society for Antimicrobial
Chemotherapy and NCCLS breakpoints. These three isolates had between 4.6- and 5.0-fold increases in
mexB transcription. None of these isolates had significant nalB mutations, but an Ala145 ﬁ Val mutation
was observed in PA3721 in two of the isolates. However, these isolates had moderately increased
production of PA3720 only. Single-strain regression analysis did not detect any major biological
differences between the different groups. Using NRI, a disk-diffusion susceptibility breakpoint of
‡ 28 mm was generated. Isolates with intermediate susceptibility to meropenem, which are considered
fully susceptible in many countries, displayed possible low-grade meropenem resistance mechanisms,
implying that the susceptibility breakpoint should be reconsidered. The increased transcription of mexB
mRNA in such isolates seems unrelated to nalB or nalC mutations.
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INTRODUCTION
Increasing carbapenem resistance in Pseudomonas
aeruginosa is currently a worldwide problem. Sus-
ceptibility rates vary in different parts of the world,
with the lowest rates seemingly being in Europe.
However, in many countries, susceptibility rates
for meropenem are somewhat higher than those for
imipenem; thus, the rates in the USA are 90.9% and
80.9%, respectively [1]. Laboratory statistics
from Karolinska University Hospital, Stockholm,
Sweden show that annual susceptibility rates for
imipenem and meropenem are equal, at c. 90% for
2001–2003 (unpublished data).
Differences in breakpoints will affect reported
susceptibility rates. The Swedish Reference Group
for Antibiotics (SRGA) (http://www.srga.org) has
chosen a more conservative approach when setting
breakpoints for meropenem than, for instance, the
British Society for Antimicrobial Chemotherapy
(BSAC), or the NCCLS [2,3]. The BSAC uses the
same laboratory standard for disk-diffusion testing
of meropenem susceptibility as the SRGA [4,5], but
has chosen not to include an intermediate suscep-
tibility category, thereby defining the susceptible
population as isolates with zone diameters
‡ 22 mm. The SRGA has defined susceptible zone
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diameters as ‡ 27 mm, and resistant zone diame-
ters as < 22 mm, leaving an intermediate suscept-
ibility category of 26–22 mm. Furthermore, the
SRGA also uses different MIC breakpoints for
meropenem, defining susceptibility as MIC values
£ 2 mg ⁄L, while the NCCLS and BSAC use
£ 4 mg ⁄L as the susceptibility breakpoint. This
conservative approach of the SRGA is likely to
reduce the number of incorrectly reported suscep-
tible isolates, but erroneous reporting of P. aerugi-
nosa as meropenem-non-susceptible can also
provide clinicians with fewer therapeutic alterna-
tives when faced with multiresistant strains.
The most important meropenem resistance
mechanisms in P. aeruginosa are believed to be
upregulation of the efflux pump MexAB–OprM
and downregulation of the porin OprD [6]. To
elucidate the biological differences between bac-
teria belonging to the different Swedish breakpoint
susceptibility categories, the transcription of genes
oprD, mexB and mexD was studied in isolates with
different levels of resistance to meropenem. In
selected isolates, mutation analysis of mexR and
PA3721, i.e., regulator genes of MexAB–OprM, was
performed, as well as analysis of transcription of
the PA3720 gene, which codes for part of a putative
MexAB–OprM activator complex [7]. As another
possible indicator of biological differences, all
isolates were also examined with single-strain
regression analysis (SRA) to compare regression
lines between isolates with different levels of
meropenem resistance. Lastly, the potential for
mathematical reconstruction of the ideal suscept-
ible population using normalised resistance inter-
pretation (NRI) was studied.
MATERIALS AND METHODS
Selection of isolates
Twenty-five clinical isolates of P. aeruginosa with varying
degrees of meropenem susceptibility were obtained from the
routine diagnostic laboratory at Karolinska University Hospi-
tal, Solna, Sweden. The 13 meropenem-non-susceptible iso-
lates, as well as the eight isolates with resistance to imipenem,
were picked randomly from a larger collection of 72 carbape-
nem-non-susceptible P. aeruginosa isolates from 2003, to rep-
resent different levels of meropenem susceptibility. The four
isolates that were susceptible to all tested antibiotics were from
patients with otitis externa. Type strain ATCC 27853 was also
included. Replicate isolates were excluded.
Eight isolates were meropenem-susceptible, but imipenem-
resistant. Three of these were derived from tracheal secretions,
two from wounds and three from urinary tract samples. The 13
meropenem-non-susceptible isolates consisted of six urinary
tract isolates, one from sputum, two from tracheal secretions,
three from wound secretions and one from pancreatic secre-
tion. Two meropenem-non-susceptible isolates were derived
from patients with cystic fibrosis.
Antimicrobial susceptibility testing
Susceptibility testing was performed by the disk-diffusion
method, using SRGA methodology and breakpoints (http://
www.srga.org). In brief, colonies were suspended in phos-
phate-buffered saline to a density of McFarland · 0.5, corres-
ponding to c. 108 CFU ⁄mL. This suspension was diluted 1:100
in phosphate-buffered saline to a final concentration of
106 CFU ⁄mL, which in P. aeruginosa produces subsequent
semi-confluent growth on agar plates. Prepared inocula were
applied to IsoSensitest agar plates by cotton swabs before
antibiotic disks were placed on the surface. Plates were
incubated at 37C for 18 h, before zone diameters were read
and interpreted according to the SRGA breakpoints [4].
Five of the isolates, including ATCC 27853, were merope-
nem-susceptible; four were fully meropenem-susceptible, but
were imipenem-resistant; four were borderline susceptible to
meropenem; five had intermediate susceptibility; four were
borderline resistant; and four were meropenem-resistant.
Among the five isolates with intermediate susceptibility to
meropenem, two were imipenem-susceptible, and the others
were imipenem-resistant.
The meropenem MIC was determined by Etest (AB Biodisk,
Solna, Sweden), as recommended by the manufacturer. All
isolates were tested on three separate occasions and the
average values were calculated. Quality assurance was per-
formed with strain ATCC 27853. MIC breakpoints were
derived from the SRGA.
Effects of efflux-pump inhibition on MIC values
To examine the contribution of efflux-pump activity to
meropenem resistance in strains hyperproducing mRNA for
mexB and mexD, MICs were determined with and without the
presence of the efflux-pump inhibitor L-phenylalanine-
L-arginine-b-naphthylamine (MC-207,110) (Sigma-Aldrich,
Stockholm, Sweden) [8]. The efflux inhibitor was incorporated
into the IsoSensitest agar at a final concentration of 40 mg ⁄L.
Real-time RT-PCR
The transcription of efflux genes mexB and mexD, porin gene
oprD, and regulator gene PA3720, was analysed using RT-PCR.
Total RNA was extracted from the isolates and synthesised
into first strand cDNA. The latter was subjected to real-time
PCR using Rotor-Gene (Corbett Research, Morlake, Australia).
A gene coding for a ribosomal protein, rpsL, was used as a
reference for normalising the transcription levels of target
genes.
Total RNA was extracted using the High Pure RNA
Isolation Kit (Roche, Mannheim, Germany). Cells were grown
overnight, diluted in a fresh culture medium (1:100) and
grown to mid-exponential phase (OD600 = 0.5). Cells were
disrupted with lysozyme (1 mg ⁄mL), and RNA extraction and
purification was performed as recommended by the manufac-
turer of the kit. Total RNA (20 ng) from all isolates was reverse
transcribed into single-stranded cDNA using a random pri-
mer. With a random primer, the reverse transcriptase in the kit
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synthesises cDNA at non-specific points along the RNA
template, thereby enabling amplification of all genes from
the same cDNA sample.
Real-time PCR was performed with Quantitect SYBR Green
(Qiagen, Hilden, Germany), using primers specific for mexB,
mexD, oprD, PA3720 and rpsL (Table 1). Amplification was
carried out in triplicate from three different cDNA prepara-
tions. For some of the isolates (ATCC 27853, isolates 14, 16 and
17), a fourth cDNA preparation was made from RNA isolated
on a separate occasion for quality assurance of the RNA
isolation procedure. The transcription level of PA3720 was
analysed only in selected isolates (ATCC 27853, isolates 1, 14,
16 and 17). To analyse the gene transcription data, Q-Gene
software was used, in which calculations are based on the
assumption that PCR amplification efficiencies for the target
gene and the reference are not equal [9]. The efficiency of
amplification was determined by amplifying seven serial ten-
fold dilutions of cDNA with rpsL primers [10].
Statistical analysis was performed with Statistica (Statsoft,
Tulsa, USA), using a two-sided t-test.
Sequencing of mexR and PA3721
Primers for sequencing mexR and PA3721 (regulator genes of
efflux pump MexAB–OprM) were designed, based on pub-
lished sequences (Table 1) [7]. DNA sequencing of PCR
products was performed with the dideoxy-chain termination
method [11]. PCR products were purified by the JETquick Spin
Column Technique (Genomed, Bad Oeynhausen, Germany).
Cycle sequencing was performed with a BigDye Terminator
Ready Reaction Kit (AB Applied Biosystems, Foster City, CA,
USA) on the GeneAmp PCR System 9700 (AB Applied
Biosystems). Extension products were purified by eth-
anol ⁄ sodium acetate precipitation, and sample electrophoresis
was performed on the ABI PRISM 3100 Genetic Analyser (AB
Applied Biosystems). Nucleotide sequences determined
experimentally were compared against sequence databases
with BLAST (http://www.ncbi.nlm.nih.gov/blast).
Single-strain regression analysis
Nine selected isolates, three each from the sensitive, interme-
diate and resistant susceptibility categories, together with
reference strain ATCC 27853, were tested at the Department of
Clinical Microbiology, Central Hospital, Va¨xjo¨. Antibiotic
disks were produced that contained six different meropenem
concentrations: 1, 5, 10, 30, 100 and 300 lg. All isolates were
tested on three separate occasions. Disk-diffusion tests were
performed according to SRGA methodology (http://
www.srga.org). Meropenem MICs were determined by agar
dilution [3]. Solutions of meropenem were mixed with Iso-
Sensitest agar in two-fold dilutions. Since SRA requires more
precise MIC values, the dilution series also included
in-between values. An inoculum of 104 CFU ⁄ spot was applied
with a multipoint inoculator. The plates were incubated at
37C for 20 h, after which the MIC was defined as the lowest
concentration that inhibited bacterial growth completely. All
isolates were tested on three separate occasions.
The single-strain regression equation can be written mathe-
matically as z2 = (A log Q) + (A log MIC) + B, where A and B
are constants, Q is the disk content of antibiotic, and z is the
disk diffusion zone diameter. The constant A will determine
the slope of the regression line, and differences in this constant
can indicate biological differences between isolates. Calcula-
tion of SRA constant A was performed using computer
software [12].
Normalised resistance interpretation
A method for reconstruction of the standard distribution of the
susceptible population of isolates in a zone diameter histogram
was used in order to compare the laboratory’s population with
the normal distribution of the ideal population of susceptible
strains (with permission from the patent holder, Bioscand AB,
Ta¨by, Sweden) [13]. The method uses the upper high-zone
values of the susceptible peak as the calibrator, since these are
not influenced by the occurrence of resistant isolates. The
mathematical reconstruction of the susceptible population
provides a Gaussian distribution curve. A lower limit can be
set for the reconstructed standard distribution, e.g., two or
three standard deviations below the mean, and all isolates with
zone values equal to or below this value can be considered
different from the susceptible population.
RESULTS
Zone diameter histogram analysis
Comparison of meropenem zone diameter histo-
grams from Karolinska University Hospital with
histograms published previously [2] revealed stri-
king similarities. The histogram for meropenem
and P. aeruginosa, including all isolates tested for
susceptibility from 2003 (1572 isolates), showed a
distribution lacking a distinct border between the
resistant and susceptible populations (Fig. 1).
To further elucidate the presence of different
sub-populations, a scatterplot was made, showing
the correlation between meropenem and imipe-
nem zone diameters in clinical isolates from
Karolinska University Hospital in 2003 (1572
isolates). The scatterplot showed that meropenem
intermediate susceptibility, according to the
SRGA, occurred in both imipenem-susceptible
and -resistant isolates (Fig. 2). Thus, it was poss-
Table 1. Primers used for real-time RT-PCR and sequen-
cing
Gene Sequence Use
oprD f 5¢-CGA CCT GCT GCT CCG CAA CTA-3¢ PCR
oprD r 5¢-TTG CAT CTC GCC CCA CTT CAG-3¢ PCR
mexB f 5¢-CAA GGG CGT CGG TGA CTT CCA G-3¢ PCR
mexB r 5¢-ACC TGG CAA CCG TCG GGA TTG A-3¢ PCR
mexD f 5¢-GGA GTT CGG CCA GGT AGT GCT G-3¢ PCR
mexD r 5¢-ACT GCA TGT CCT CGG GGA AGA A-3¢ PCR
rspl f 5¢-GCT GCA AAA CTG CCC GCA ACG-3¢ PCR
rspl r 5¢-ACC CGA GGT GTC CAG CGA ACC-3¢ PCR
PA3720 f 5¢-TCG CCC TGG TCT ATC CGC CGC TC-3¢ PCR
PA3720 r 5¢-CCG CTC AGC AGT GCC TTC GCC AT-3¢ PCR
mexR f 5¢-GAA GGC ATT CGC CAG TAA-3¢ Sequencing
mexR r 5¢-GGC TGG CGT TCG TTG CAT-3¢ Sequencing
PA3721 f 5¢-TCA ACC CTA ACG AGA AAC GCT-3¢ Sequencing
PA3721 r 5¢-TCC ACC TCA CCG AAC TGC-3¢ Sequencing
664 Clinical Microbiology and Infection, Volume 11 Number 8, August 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 662–669
ible to divide the meropenem-intermediate iso-
lates into two categories.
Effects of efflux-pump inhibition on MICs
In the three meropenem isolates with intermedi-
ate susceptibility (nos. 14, 16 and 17) with signi-
ficantly increased levels of mRNA for mexB, an
MIC reduction from 4 to 2 mg ⁄L was observed
(Table 2). MIC reductions of one to three dilution
steps were observed in five of the eight merope-
nem-resistant isolates (nos. 18 and 20–23).
Gene transcription analysis
In the group of meropenem-susceptible isolates,
significant reduction of oprD transcription and
increase of mexD transcription, compared to
ATCC 27853 (p < 0.05), was observed for some
of the isolates (Table 2). All isolates displaying
this pattern of transcription were imipenem-
resistant. None of the isolates had increased mexB
mRNA levels. The imipenem-susceptible isolates
in this group had no significant changes in
transcription of resistance genes. Among the
imipenem-resistant isolates, transcription of oprD
was between 0.04- and 0.6-fold compared to
ATCC 27853, while the amount of mexD mRNA
varied from 0.4- to 5.8-fold compared to the type
strain. No differences in gene transcription were
observed between isolates with disk-diffusion
zone diameter values close to the intermediate
susceptibility breakpoint and isolates with zone
diameter values in the middle of the susceptibility
interval.
Isolates belonging to the intermediate category
proved to be heterogeneous with regard to gene
transcription. Three of the isolates in this group
were imipenem-resistant, while two were imipe-
nem-susceptible. One of the isolates (no. 13) had a
meropenem MIC of 2 mg ⁄L and displayed a
significant reduction only in oprD transcription
(0.2-fold compared to ATCC 27853). The same
pattern of gene transcription was observed in
isolate no. 15, which had a meropenem MIC of
4 mg ⁄L and a very low oprD mRNA level of
1 · 10)6-fold that of the ATCC type strain.
Another imipenem-resistant isolate (no. 14)
with a meropenem MIC of 4 mg ⁄L showed
significantly decreased oprD transcription, but
significantly increased mexB and mexD transcrip-
tion (5.0- and 6.8-fold that of the ATCC type
strain, respectively). One of the imipenem-sus-
ceptible isolates in this group (no. 16) had a
meropenem MIC of 4 mg ⁄L and a 4.9-fold
increase in mexB transcription, as well as a
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Fig. 1. Zone diameter histogram for
Pseudomonas aeruginosa and
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5.0-fold increase in mexD transcription (both
significant), while transcription of oprD was not
altered significantly. The other imipenem-sus-
ceptible isolate (no. 17) showed significantly
increased mexB and mexD transcription (4.6- and
13.5-fold that of the reference strain, respectively).
Surprisingly, this last isolate also showed signifi-
cant downregulation of oprD transcription
(0.3-fold that of the type strain).
Transcription of PA3720 was analysed only in
selected isolates in the meropenem-intermediate
group that had increased transcription of mexB.
Isolates 14 and 16 showed slightly increased
transcription of PA3720 (2.5- and 2.3-fold that of
the reference strain, respectively).
Meropenem-resistant strains were divided into
two groups according to disk-diffusion zone
diameters—one group with resistant and one
group with borderline-resistant isolates. MICs
did not differ between the two groups. Only
two isolates (nos. 23 and 25) had an MIC
‡ 16 mg ⁄L, while the others had MICs of
8 mg ⁄L, meaning that they would be classified
as intermediately-susceptible isolates according to
the SRGA, NCCLS and BSAC MIC breakpoints.
Downregulation of oprD, ranging from 0.6 · 10)6-
to 1 · 10)6-fold that of the type strain, and
increased mexB transcription, varying from 3.6-
to 17.6-fold, was observed in all isolates, except
one (no. 19).
Transcription of mexD was elevated signifi-
cantly in 11 isolates (nos. 5, 6, 7, 14, 16–18, 21, 22,
24 and 25), with values ranging from 2.3- to 17.2-
fold that of the type strain. One isolate (no. 19)
showed no significant changes in transcription of
any of the resistance genes examined.
Mutation analysis of mexR and PA3721
Regulator genes of MexAB–OprM were sequenced
in the ATCC type strain, as well as in three
meropenem-intermediate isolates with increased
transcription of mexB (nos. 14, 16 and 17). In isolate
14, a Val126 ﬁ Glu substitution was found in
regulator gene mexR. This mutation has been
observed previously in susceptible wild-type iso-
lates and is considered to be non-significant
[14,15]. No mexR mutations were found in the
Table 2. Antibiograms and gene transcription levels of all isolates
Strain Group
Antibiogram (disk-diffusion) MIC
MEM
(mg ⁄L)
MIC
MEM + MC
(mg ⁄L)
Zone diameter
MEM (mm)
Gene transcription (compared to ATCC
27853)
MEM IPM PIP CAZ CIP orpD mexB PA3720 mexD
ATCC 1 S S S S S 0.25 0.25 36 1 1 1 1
1 1 S S S S S 0.125 0.25 40 1.0 1.0 1.5 0.8
2 1 S S S S S 0.125 0.125 38 1.2 0.9 ND 0.9
3 1 S S S S S 0.125 0.125 37 1.2 1.4 ND 0.9
4 1 S S S S S 0.125 0.125 37 0.7 1.5 ND 0.8
5 2 S R S S S 0.25 0.25 38 0.1a 2.5 ND 5.8a
6 2 S R S S S 0.5 0.5 36 0.04a 1.1 ND 3.2a
7 2 S R S S S 0.5 0.5 33 0.01a 2.8 ND 4.8a
8 2 S R S S S 1 1 30 0.000001a 1.6 ND 1.5
9 3 S R S S S 2 2 28 0.09a 0.6 ND 0.4
10 3 S R S S S 2 1 28 0.6a 0.8 ND 1.5
11 3 S R S S R 2 2 27 0.6a 3.1 ND 3.0
12 3 S R S S R 2 1 27 0.6a 0.1 ND 2.0
13 4 I R S S S 2 2 26 0.2a 2.1 ND 2.1
14 4 I R S S S 4 4 25 0.0003a 5.0a 2.5a 6.8a
15 4 I R S S S 4 4 24 0.000001a 2.5 ND 1.4
16 4 I S S S S 4 2 23 1.5 4.9a 0.9 5.0a
17 4 I S S I R 4 2 23 0.3a 4.6a 2.3a 13.5a
18 5 R R S S S 8 4 21 0.6a 6.9a ND 17.2a
19 5 R R S S S 8 8 21 1.5 0.7 ND 2.1
20 5 R R S S S 8 4 20 0.000001a 6.4a ND 0.5
21 5 R R S S R 8 2 19 0.0004a 11.5a ND 8.5a
22 6 R S I I R 8 4 18 0.4a 17.6a ND 2.3a
23 6 R R R R S 16 2 15 0.001a 9.3a ND 3.4
24 6 R R R R S 8 8 14 0.03a 3.6a ND 3.5a
25 6 R R R S R > 32 > 32 13 0.04a 8.2a ND 2.3a
aStatistically significant increase or decrease in gene transcription compared to ATCC 27853 (p < 0.05).
MER, meropenem; IPM, imipenem; PIP, piperacillin; CAZ, ceftazidime; CIP, ciprofloxacin; MC, MC-207,110 (L-phenylalanine-L-arginine-b-naphthylamine); ND, not
determined.
Antibiograms are based on disk-diffusion susceptibility testing with breakpoints derived from the Swedish Reference Group for Antibiotics.
MIC testing was performed by Etest, using only two-step dilution values (average of two).
Explanation of groups: 1 = meropenem- and imipenem-susceptible (‡ 27 mm); 2 = meropenem-susceptible and imipenem-resistant; 3 = meropenem borderline-susceptible
and imipenem-resistant (27–28 mm), 4 = meropenem intermedately-susceptible (26–22 mm); 5 = meropenem borderline-resistant (20–21 mm); 6 = meropenem-resistant
(< 22 mm).
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ATCC strain and isolates 16 and 17. Isolates 14
and 16 had several mutations in PA3721. A
Gly71 ﬁ Glu mutation and a Ser209 ﬁ Arg muta-
tion was observed in both isolates; these mutations
have been described previously in wild-type
isolates [7]. The two isolates also had an addi-
tional Ala145 ﬁ Val mutation of uncertain signi-
ficance.
Single-strain regression analysis
The mean value of the A constant for the different
isolates was 746.9 (± 40.4), while the correspond-
ing value for the B constant was 64.2 (± 61.4). The
lack of any difference between isolates with
highly different MIC values indicated that SRA
did not detect any major biological differences
between isolates with variable levels of merope-
nem resistance.
Normalised resistance interpretation
Reconstruction of the fully susceptible peak by
NRI gave the distribution shown in Fig. 3. For
isolates from 2003, the calculated mean for the
susceptible population was 38.4 mm
(SD = 4.3 mm). The corresponding mean values
from 2001 and 2002 were 38.5 (SD = 4.6 mm)
and 37.4 mm (SD = 4.7 mm), respectively. From
the mean value, a lower limit was calculated.
Setting the breakpoint at 2 · SD (theoretically
including 97.7% of the susceptible strains),
2.5 · SD (including 99.4%) or 3 · SD (including
99.9%) below the mean value yielded lower
zone diameter limits of 30, 28 or 26 mm,
respectively.
DISCUSSION
Several approaches are possible when setting
breakpoints, but whichever method, or combina-
tion of methods, is used, it is important to avoid
reporting resistant isolates as susceptible. One
strategy to avoid this is to define an intermedi-
ately-susceptible population, constituting a buffer
zone between the susceptible and the resistant
populations. In many cases, defining the resistant,
intermediate and susceptible populations can be
an easy task, but in the case of meropenem and
P. aeruginosa, a clear distinction between these
categories has proved difficult to achieve [2].
Another possible strategy is to define the
susceptible population as isolates with no resist-
ance mechanisms for a given antibiotic. This can
be accomplished, for instance, by looking at the
MIC distribution in wild-type populations that
are naive to the examined antibiotic, a method
that the SRGA has applied when defining the
lower border of the meropenem-susceptible pop-
ulation at 27 mm [16]. Furthermore, in mixed
populations, the susceptible peak in zone diam-
eter histograms can be reconstructed mathemat-
ically by NRI [13]. Other approaches could
involve application of pharmacological data, or,
as in the present study, the study of resistance
mechanisms in isolates with different MICs of a
certain antibiotic. A problem with the latter
approach is that all resistance mechanisms might
not be known for a certain drug–microbe combi-
nation. However, in the case of meropenem and
P. aeruginosa, there is accumulating evidence that
antibiotic efflux and reduced permeability are the
major resistance mechanisms [6], making the
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transcription of these resistance genes a relevant
indicator of the meropenem-resistant genotype.
The gene transcription levels observed in the
isolates studied confirm that isolates with high-
level resistance (Table 2; group 5) have increased
transcription of efflux gene mexB, coding for a
component of the (presumably) most important
efflux pump, MexAB–OprM [6]. Transcription of
mexD did not correlate clearly with the level of
meropenem resistance. This probably reflects the
fact that the MexCD–OprJ efflux pump plays a
more complementary role in conferring carbape-
nem resistance to P. aeruginosa.
A reduction in oprD mRNA was seen in all
isolates, except the fully susceptible isolates, an
isolate that was imipenem-susceptible (no. 11),
and one isolate that was imipenem-resistant
(no. 13). The imipenem-resistant isolate with
normal transcription of oprD also showed un-
changed transcription of the efflux genes. This
finding could be related to the presence of
mutationally changed oprD and ⁄ or mexB mRNA,
giving rise to a functionally defective protein [17],
or, alternatively, to the presence of other resist-
ance mechanisms, such as a change in penicillin-
binding proteins or other, so far undescribed,
resistance mechanisms [18].
Distinguishing borderline-resistant isolates
(Table 2; group 4) from isolates with high-level
resistance (Table 2; group 5) proved difficult on
the basis of gene transcription levels. However,
these two groups were also not distinguished by
meropenem MICs, indicating that the relevance of
the minor zone diameter differences is difficult to
interpret. These isolates would, according to their
MIC values, be reported as intermediately-resist-
ant, except two isolates (nos. 17 and 19) with
meropenem MICs of 16 mg ⁄L. Considering that
almost all these isolates had high levels of mexB
mRNA, it is uncertain whether isolates with MICs
of 8 mg ⁄L should be regarded as resistant. Dis-
tinguishing susceptible (Table 2; group 1) and
borderline-susceptible isolates (Table 2; group 2)
by gene transcription levels also proved imposs-
ible. The two groups had different MICs, but gene
transcription analysis is probably not sensitive
enough to detect subtle differences in susceptibil-
ity levels. There is also a possibility that other, so
far undescribed, resistance mechanisms could
play a role in some isolates. The isolates in these
two groups all had downregulation of oprD, but
no change in mexB transcription.
The most interesting findings were made in the
intermediate group, defined as isolates with zone
diameters of 26–22 mm, or with MICs > 2 mg ⁄L
and £ 8 mg ⁄L. It was expected that many of
the isolates designated as intermediate by the
Swedish guidelines would be deficient in the
OprD porin, making them imipenem-resistant,
but probably still susceptible to meropenem, since
meropenem resistance is regarded as resulting
from a combination of porin deficiency and efflux
[6,19]. Two of the isolates in this group showed
downregulation of oprD only, but the three other
isolates also had significant upregulation of mexB
and mexD. However, no nalB or nalC mutations
could be found in these three isolates. Still, the
regulation of MexAB–OprM expression seems to
be complex [7], and several other regulator genes
may be involved, including genes that might
cause low-level increases in the amount of efflux
protein only. Interestingly, one of the isolates in
this group (no. 16) was imipenem-susceptible,
having a normal oprD transcription level. This
isolate had an MIC of 4 mg ⁄L, resulting presum-
ably from upregulation of efflux genes only.
Furthermore, one imipenem-susceptible isolate
(no. 17) had a significantly decreased level of
oprD mRNA. The reason why this isolate was still
imipenem-susceptible is unclear, but one explan-
ation could be that the decrease in oprD mRNA
was relatively modest.
SRA did not detect any biological differences
between isolates in the present study. This finding
indicates that SRA is a suitable method for the
calibration of meropenem disk-diffusion suscep-
tibility tests, since the results seem to be relatively
independent of resistance to the examined anti-
biotic. In contrast, NRI proved to be useful in
reconstructing the ideal susceptible population.
Taking into consideration the gene transcription
data, it would be natural to set the susceptibility
breakpoint at 2.5 · SD from the mean, i.e., 28 mm.
Therefore, it would be possible to avoid reporting
mexB mRNA hyperproducers as fully susceptible
to meropenem. The corresponding MIC break-
point for susceptible isolates would be £ 2 mg ⁄L,
according to the SRA equation.
The findings in the group showing intermedi-
ate resistance to meropenem suggest that this is a
heterogeneous group, comprising isolates with
possible low-grade meropenem resistance mech-
anisms. Thus, it could be argued that these
isolates, statistically and biologically, should be
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distinguished from the fully susceptible popula-
tion. There is also limited evidence regarding the
relationship between pathogen eradication and
in-vitro susceptibility to meropenem [20], indica-
ting that it is indeed difficult to draw conclusions
on breakpoints from clinical data. Until more
extensive clinical or biological data are available,
it is questionable whether isolates with merope-
nem zone diameters of < 27 mm or MICs of
> 2 mg ⁄L should be regarded as fully merope-
nem-susceptible. One possible strategy for over-
coming the difficulty of defining the border
between the fully susceptible group and the
intermediate group could be a mathematical
reconstruction of the susceptible population,
using NRI.
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